Literature DB >> 9427612

Enhancement of T cell-independent immune responses in vivo by CD40 antibodies.

P Dullforce1, D C Sutton, A W Heath.   

Abstract

In this report we describe a potentially powerful method for vaccinating infants against encapsulated bacterial pathogens such as Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis. High levels of antibody directed against the polysaccharides of the bacterial capsule are normally protective. Unfortunately, the capsular polysaccharides are T cell-independent antigens (TI); lacking T-cell help, they induce only weak, predominantly IgM antibody responses, with infants responding especially poorly. T-cell help, given to B cells during responses to protein antigens, causes stronger antibody responses and isotype switching to the IgG isotypes. T-cell help is mainly mediated through ligation of the B-cell surface antigen, CD40, by its cognate T-cell ligand, CD154. Here we show that administering anti-CD40 monoclonal antibody to mice, along with pneumococcal polysaccharide, provides a substitute for T-cell help and results in the generation of strong, isotype-switched antibody responses, which are protective. The work points the way toward a possible effective and inexpensive means of protecting susceptible groups against important bacterial pathogens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427612     DOI: 10.1038/nm0198-088

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  32 in total

1.  B cell immunopoiesis: visualizing the impact of CD40 engagement on the course of T cell-independent immune responses in an Ig transgenic system.

Authors:  L D Erickson; L A Vogel; M Cascalho; J Wong; M Wabl; B G Durell; R J Noelle
Journal:  Eur J Immunol       Date:  2000-11       Impact factor: 5.532

2.  Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: modulation of serologic response, epitope specificity, and isotype.

Authors:  J Y Wu; R K Taylor; W F Wade
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 3.  Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

Authors:  C G Vinuesa; C de Lucas; M C Cook
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

4.  Short-circuiting long-lived humoral immunity by the heightened engagement of CD40.

Authors:  Loren D Erickson; Brigit G Durell; Laura A Vogel; Brian P O'Connor; Marilia Cascalho; Teruhito Yasui; Hitoshi Kikutani; Randolph J Noelle
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

5.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

6.  Systemic treatment with anti-CD40 antibody stimulates Langerhans cell migration from the skin.

Authors:  S Jolles; J Christensen; M Holman; G B Klaus; A Ager
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 7.  T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens.

Authors:  A Jeurissen; J L Ceuppens; X Bossuyt
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

8.  Functional activity of CD40 antibodies correlates to the position of binding relative to CD154.

Authors:  T A Barr; A W Heath
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

Review 9.  Peptide-displaying phage technology in glycobiology.

Authors:  Michiko N Fukuda
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

10.  CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis.

Authors:  Vijay Ns Bhagawati-Prasad; Evy De Leenheer; Nadine P Keefe; Lorna A Ryan; Jennifer Carlring; Andrew W Heath
Journal:  J Immune Based Ther Vaccines       Date:  2010-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.